US › Healthcare

Niagen Bioscience, Inc. (NAGE)

US · Healthcare · Biotechnology

$3.47-1.70%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$31.5M
Revenue YoY
+3.3%
Net profit
$6.3M
Profit YoY
+24.8%
EPS
$0.02
EPS estimate
$0.06
Net margin
20.1%

EPS came in at 0.02 against a street estimate of 0.06 — a miss of 66.7%.

Key statistics

Market cap
$281.1M
P/E
16.8
Forward P/E
13.6
P/B
3.29
Book value
$1.03
EPS (TTM)
$0.21
52-week high
$11.29
52-week low
$3.12
50-day MA
$3.45
200-day MA
$5.17
Beta
2.10

Analyst view

Analysts rate Niagen Bioscience, Inc. a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $12.50.

Shareholding

Insiders
29.26%
Institutions
46.96%

Largest institutional holders

FundStake
BlackRock Inc4.86%
Steel Peak Wealth Management LLC4.39%
Vanguard Group Inc4.13%
Arrowstreet Capital Limited Partnership2.99%
Vanguard Capital Management, LLC2.70%
Tieton Capital Management, LLC2.55%
Qube Research & Technologies2.15%
UBS Group AG1.76%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Niagen Bioscience, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.